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MICAbstract In the present study, a novel series of 2-{5-[4-(1-aza-2-(2-thienyl)vinyl)phenyl](1,3,4-oxa-
diazol-2-ylthio)}-N-arylacetamides (IV)1–12 were synthesized and tested for their antimicrobial
activity. Newly synthesized compounds were screened for their antibacterial and antifungal activi-
ties on Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus pyogenes,
Candida albicans, Aspergillus niger and Aspergillus clavatus. The chemical structures of newly syn-
thesized compounds were elicited by IR, 1H NMR, 13C NMR and mass spectral data. The synthe-
sized bio-active compounds exhibited excellent to moderate antimicrobial activity. Compounds
(IV)5, (IV)6 and (IV)7 possess excellent antibacterial activity whereas compounds (IV)6, (IV)9 and
(IV)11 possess excellent antifungal activity.
ª 2011 King Saud University. Production and hosting by Elsevier B.V.D license.1. Introduction
As resistance to antimicrobial drugs is widespread, there is an
increasing need for identiﬁcation of novel structure leads that
may be of use in designing new, potent, and less toxic antimicro-
bial agents. The multiple pharmacological actions of unique
synthetic compounds are a prerequisite for classifying a drugas highly efﬁcacious, because these actions offer possibility of
treating various diseases. 1,3,4-Oxadiazoles are an important
class of heterocyclic compounds with broad spectrum of biolog-
ical activities and are commonly utilized pharmacophores due
to their metabolic proﬁle and ability to engage in hydrogen
bonding. In particular, marketed antihypertensive agents such
as tiodazosin (Vardan et al., 1983) and nesapidil (Schlecker
and Thieme, 1988) as well as antibiotics such as furamizole
(Ogata et al., 1971) contain oxadiazole nucleus. During the past
years, considerable evidences have accumulated to demonstrate
the efﬁcacy of 1,3,4-oxadiazole including antimicrobial (Prasad
et al., 2008), anti-inﬂammatory, analgesic (Kashaw et al., 2010),
anti-HIV (Sriram et al., 2009), antimycobacterial (Macaey et al.,
2005), cathepsin K inhibitors (Palmer et al., 2006), tyrosinase
inhibitors (Khan et al., 2005), monoamine oxidase (MAO)
inhibitors (Ke et al., 2008) and anticonvulsant (Almasirad
et al., 2004) properties. 1,3,4-Oxadiazole-carboxamides con-
taining different lipophilic moieties (i.e. 4-diphenyl, 1-napthyl,
phenyl propyl and n-hexyl substituents) and additional basic
groups which are mainly alkyl and amino alkyl residues have
256 N.C. Desai et al.been recently described as antiplatelet and antithrombotic com-
pounds as well as serotonin antagonist (Bethge et al., 2005). 2-
Amino-1,3,4-oxadiazole has demonstrated biological activity
as a muscle relaxant (Yale and Losee, 1966), while biarylpyraz-
olyl oxadiazole behaves as potent, selective, orally bioavailable
cannabinoid-1 receptor antagonist for the treatment of obesity
(Lee et al., 2008).
Moreover thiophene derivatives are undoubtedly one of the
most important class of heterocycles, because some of thio-
phene skeleton containing molecules have been reported to ex-
hibit interesting pharmaceutical properties including
antimicrobial (Queiroz et al., 2006), anticancer (Thomson
et al., 2006), anti-inﬂammatory (Kumar et al., 2004), bacterio-
static and fungistatic activity (Kipnis et al., 1949). Some other
derivatives exhibit a strong inhibition of NHE-1 and cardio-
protective efﬁcacy (Cho et al., 2005).
Looking at the medicinal importance of 1,3,4-oxadiazole
and thiophene moieties, we report here the synthesis of a
new class of heterocyclic molecules in which both the moieties
are present and attempt to develop potential bioactive mole-
cules. The structures of synthesized compounds were assigned
on the basis of IR, 1H NMR, 13C NMR, and mass spectral
data. These compounds were evaluated for their antimicrobial
screening on different strains of bacteria and fungi.
2. Experimental
2.1. Materials and physical measurements
All reactions except those in aqueous media were carried out
by standard techniques for the exclusion of moisture. All reac-
tion courses and product mixtures were routinely monitored
by aluminium coated thin-layer chromatography (TLC) plates
60 F245 (E. Merck) and visualized with ultraviolet (UV) light,
or iodine vapour. Melting points were determined on an elec-
tro thermal melting point apparatus and are reported uncor-
rected. Elemental analysis (% C, H, N) was carried out by a
Perkin–Elmer 2400 CHN analyser. IR spectra of all com-
pounds have been recorded on a Perkin–Elmer FT-IR spectro-
photometer in KBr. 1H NMR and 13C NMR spectra were
recorded on a Bruker (400 MHZ) spectrometer using
DMSO-d6 as a solvent and TMS as an internal standard.
Chemical shifts are reported in parts per million (ppm). Mass
spectra were scanned on a Schimadzu LCMS 2010 spectropho-
tometer. Anhydrous reactions were carried out in oven-dried
glassware in nitrogen atmosphere. In the conventional method,
compounds were synthesized by using Random synthesizer.
Bookie Rotavapour is used for distillation. The completion
of the reaction and the purity of all compounds were checked
on aluminium coated TLC plates 60 F245 (E. Merck) using
hexane-ethyl acetate (7.5:2.5 V/V) as mobile phase and visual-
ized with ultraviolet (UV) light, or iodine vapour.
2.2. Preparation methods and physical data of synthesized
compounds (I) to (IV)1–122.2.1. Procedure for the synthesis of N-amino(4-
aminophenyl)carboxamide (I)
Compound N-amino(4-aminophenyl)carboxamide (I) was pre-
pared according to the literature method (Mathew et al., 2006).2.2.2. Procedure for the synthesis of 5-(4-aminophenyl)-1,3,4-
oxadiazole-2-thiol (II)
A mixture of N-amino(4-aminophenyl)carboxamide (I)
(0.1 mol), potassium hydroxide (0.1 mol), carbon disulﬁde
(0.1 mol) and ethanol (20 mL) was heated under reﬂux until
the evolution of hydrogen sulﬁde ceased . The reaction mixture
was cooled to room temperature and poured into ice cold
water (100 mL). It was neutralized with dilute hydrochloric
acid. The precipitated solid was ﬁltered, washed with water
and the dried product was recrystallized from ethanol. Yield:
70%; white powder; m.p.: 257–259 C; IR (KBr, cm1): 3350
and 3418 (N–H stretching, primary amine), 3050 (C–H stretch-
ing, aromatic ring), 1625, 1587, 1556 (C‚N, C‚C stretching,
aromatic ring), 1206 (C–O–C stretching, oxadiazole); 1H
NMR (400 MHz, DMSO-d6, d, ppm): 6.31 (s, 2H, NH2),
6.45–7.60 (m, 4H, Ar–H), 13.21 (s, 1H, SH); 13C NMR
(400 MHz, DMSO-d6, d, ppm): 116.4 (C-5, 7), 118.1 (C-3) ,
127.6 (C-4, 8) 143.6 (C-6), 161.2 (C-1), 171.3 (C-2); LCMS
(m/z): 193 (M+). Found: C-49.67, H-3.62, N-21.78; Anal.
Calcd. For C8H7N3OS (193.03): C-49.73, H-3.65, N-21.75%.
2.2.3. Procedure for the synthesis of 5-[4-(1-aza-2-(2-
thienyl)vinyl)phenyl]-1,3,4-oxadiazole-2-thiol (III)
Compound (II) (0.1 mol) was dissolved in ethanol (75 mL).
Then, thiophene-2-carbaldehyde (0.1 mol) was added drop
wise. The reaction mixture was reﬂuxed for 5 h. Excess of sol-
vent was distilled off and the mixture was allowed to cool at
room temperature. The separated product was ﬁltered, washed
with cold water, dried and recrystallized from ethanol. Yield
78%; white crystal; m.p.: 191–194 C; IR (KBr, cm1): 3338
(–NH stretching, secondary amine), 3050 (C–H stretching, aro-
matic ring), 1627, 1590, 1554 (C‚N, C‚C stretching, aro-
matic ring), 1203 (C–O–C stretching, oxadiazole); 1H NMR
(400 MHz, DMSO-d6, d, ppm): 6.74–7.85 (m, 7H, Ar–H),
8.21 (s, 1H, –CH‚N–), 13.24 (s, 1H, SH); 13C NMR
(400 MHz, DMSO-d6, d, ppm): 120.1 (C-5, 7), 124.4 (C-3),
127.3 (C-12), 128.2 (C-4, 8), 128.6 (C-13), 130 (C-11), 141.4
(C-10), 147.6 (C-6), 149.7 (C-9), 161.3 (C-1), 171.4 (C-2);
LCMS (m/z): 287 (M+). Found: C-54.21, H-3.20, N-14.53;
Anal. Calcd. For C13H9N3OS2 (287.02): C-54.34, H-3.16, N-
14.62%.
2.2.4. General Procedure for the synthesis 2-{5-[4-(1-aza-2-(2-
thienyl)vinyl)phenyl](1,3,4-oxadiazol-2-ylthio)}-N-
arylacetamides (IV)1–12
In a round bottomed ﬂask, compound 3 (0.01 mol) was dis-
solved in an aqueous solution of potassium hydroxide
(25%). The reaction mixture was heated at 80 C and different
substituted a-chloro acetanilide (0.015 mol) in ethanol (10 mL)
was added with constant stirring followed by reﬂuxing it for
2 h. The contents were left overnight. The crystals were ﬁl-
tered, washed with water, dried and recrystallized from
ethanol.
2.2.4.1. 2-{5-[4-(1-Aza-2-(2-thienyl)vinyl)phenyl](1,3,4-oxa-
diazol-2-ylthio)}-N-phenyl-acetamide (IV)1. Yield: 61%; white
crystal; m.p.: 270–272 C; IR (KBr, cm1): 3334 (–NH stretch-
ing, secondary amine), 3087, 3054 (C–H stretching, aromatic
ring), 2868 (C–H stretching, –CH2–), 1714 (C‚O stretching,
amide), 1624, 1586, 1554 (C‚N, C‚C, aromatic ring stretch-
ing), 1450 (C–H bending, –CH2–), 1204 (C–O–C stretching,
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2H, –S–CH2–), 6.52–7.78 (m, 12H, ArH), 8.15 (s, 1H,
–CH‚N–), 10.20 (s, 1H, –CONH–); 13C NMR (400 MHz,
DMSO-d6, d, ppm): 32.5 (C-14), 119.7 (C-7, 11), 121.5 (C-
17), 124.5 (C-9), 127.3 (C-2), 128.0 (C-19), 128.3 (C-3), 128.5
(C-19), 128.9 (C-1), 129.2, 131.2 (C-8, 10), 139.5 (C-16),
141.4 (C-4), 147.6 (C-6) 149.9 (C-5), 161.3 (C-12), 164.6 (C-
15), 171.1 (C-13); LCMS (m/z): 420 (M+). Found: C-59.95,
H-3.95, N-13.35; Anal. Calcd. For C21H16N4O2S2 (420.07):
C-59.98, H-3.83, N-13.32%.
2.2.4.2. 2-{5-[4-(1-Aza-2-(2-thienyl)vinyl)phenyl](1,3,4-oxa-
diazol-2-ylthio)}-N-(2-chloro-phenyl)acetamide (IV)2. Yield:
57%; light yellow crystal; m.p.: 221–223 C; IR (KBr, cm1):
3334 (–NH stretching, secondary amine), 3085, 3057 (C–H
stretching, aromatic ring), 2864 (C–H stretching, –CH2–),
1712 (C‚O stretching, amide), 1621, 1586, 1552 (C‚N,
C‚C, aromatic ring stretching), 1452 (C–H bending, –CH2–),
1208 (C–O–C stretching, oxadiazole), 780 (C–Cl); 1H NMR
(400 MHz, DMSO-d6, d, ppm): 4.03 (s, 2H, –S–CH2–), 6.54–
7.79 (m, 11H, ArH), 8.13 (s, 1H, –CH‚N–), 10.21 (s, 1H, –
CONH); 13C NMR (400 MHz, DMSO-d6, d, ppm): 32.5 (C-
14), 119.6, (C-7, 11) 121.6 (C-21), 124.2 (C-20), 124.4 (C-9),
126.3 (C-17), 127.3 (C-2), 128.4 (C-3), 129 (C-1), 130.1 (C-
18), 131.1 (C-19), 131.2 (C-8, 10), 133.9 (C-16), 141.4 (C-4),
147.6 (C-6), 149.7 (C-5), 161.3 (C-12), 164.5 (C-15), 171.3
(C-13); LCMS (m/z): 454 (M+). Found: C-55.40, H-3.38, N-
12.40; Anal. Calcd. For C21H15ClN4O2S2 (454.03): C-55.44,
H-3.32, N-12.31%.
2.2.4.3. 2-{5-[4-(1-Aza-2-(2-thienyl)vinyl)phenyl](1,3,4-oxa-
diazol-2-ylthio)}-N-(2-nitro-phenyl)acetamide (IV)3. Yield:
69%; yellow crystal; m.p.: 150–152 C; IR (KBr, cm1): 3338
(–NH stretching, secondary amine), 3087, 3053 (C–H stretch-
ing, aromatic ring), 2869 (C–H stretching, –CH2–), 1718
(C‚O stretching, amide), 1623, 1583, 1556 (C‚N, C‚C, aro-
matic ring stretching), 1485 (NO2 group, asymmetric stretch-
ing), 1456 (C–H bending, –CH2–), 1352 (NO2 group,
symmetric stretching), 1206 (C–O–C stretching, oxadiazole);
1H NMR (400 MHz, DMSO-d6, d, ppm): 4.05 (s, 2H, –S–
CH2–), 6.62–7.89 (m, 11H, ArH), 8.16 (s, 1H, –CH‚N),
10.23 (s, 1H, –CONH–); 13C NMR (400 MHz, DMSO-d6, d,
ppm): 32.6 (C-14), 119.8 (C-7, 11), 124.5 (C-9), 125 (C-21),
125.1 (C-19), 125.3 (C-18), 127.3 (C-2), 128.6 (C-3), 129.1
(C-1), 129.9 (C-16), 131.1 (C-20), 131.2 (C-8, 10), 139.4 (C-
17), 141.6 (C-4), 147.8 (C-6), 149.9 (C-5), 161.2 (C-12), 164.4
(C-15), 171.4 (C-13); LCMS (m/z): 465 (M+). Found: C-
54.19, H-3.11, N-15.07; Anal. Calcd. For C21H15N5O4S2
(465.06): C-54.18, H-3.24, N-15.04%.
2.2.4.4. 2-{5-[4-(1-Aza-2-(2-thienyl)vinyl)phenyl](1,3,4-oxa-
diazol-2-ylthio)}-N-(2-methyl-phenyl)acetamide (IV)4. Yield:
77%; white crystal; m.p.: 210–213 C; IR (KBr, cm1): 3334
(–NH stretching, secondary amine), 3086, 3057 (C–H stretch-
ing, aromatic ring), 2864, 2942 (C–H stretching, –CH2–,
–CH3), 1712 (C‚O stretching, amide), 1621, 1584, 1553
(C‚C, C‚N stretching, aromatic ring), 1450, 1401 (C–H
bending, –CH2–, –CH3), 1202 (C–O–C stretching, oxadiazole);
1H NMR (400 MHz, DMSO-d6, d, ppm): 2.12 (s, 3H, –CH3),
4.00 (s, 2H, –S–CH2–), 6.53–7.72 (m, 11H, ArH), 8.10 (s, 1H,
–CH‚N), 10.20 (s, 1H, –CONH–); 13C NMR (400 MHz,
DMSO-d6, d, ppm): 23.4 (C-22), 32.4 (C-14), 119.6 (C-7, 11),124.5 (C-9), 124.9 (C-17), 125.5 (C-18), 127.1 (C-2), 128.8
(C-19), 128.4 (C-3), 129.2 (C-19), 130.7 (C-20), 131.2 (C-8,
10), 131.6 (C-21), 137.5 (C-16), 141.3 (C-4), 147.8 (C-6),
149.7 (C-5), 161.3 (C-12), 164.4 (C-15), 171.4 (C-13); LCMS
(m/z): 434 (M+). Found: C-60.73, H-4.30, N-12.88; Anal.
Calcd. For C22H18N4O2S2 (434.08): C-60.80, H-4.17, N-
12.89%.
2.2.4.5. 2-{5-[4-(1-Aza-2-(2-thienyl)vinyl)phenyl](1,3,4-oxa-
diazol-2-ylthio)}-N-(2,4-di-methylphenyl)acetamide (IV)5.
Yield: 71%; m.p.: light pink crystal; 122–124 C; IR (KBr,
cm-1): 3336 (–NH stretching, secondary amine), 3086, 3056
(C–H stretching, aromatic ring), 2874, 2943 (C–H stretching,
–CH2–, –CH3), 1715 (C‚O stretching, amide), 1620, 1583,
1556 (C‚C, C‚N stretching, aromatic ring), 1445, 1403
(C–H bending, –CH2–, –CH3), 1202 (C–O–C stretching, oxadi-
azole); 1H NMR (400 MHz, DMSO-d6, d, ppm): 2.01 (s, 6H,
–CH3), 4.00 (s, 2H, –S–CH2–), 6.52–7.83 (m, 10H, ArH),
8.12 (s, 1H, –CH‚N), 10.10 (s, 1H, –CONH–); 13C NMR
(400 MHz, DMSO-d6, d, ppm): 21.2 (C-22), 25.4 (C-23), 32.3
(C-14), 114.7 (C-17), 119.7 (C-7, 11), 124.7 (C-9), 126.2 (C-
18), 127.1 (C-2), 128.6 (C-3), 129 (C-1), 131.1 (C-8, 10),
131.5 (C-20), 132.8 (C-16), 134.3 (C-21), 141.4 (C-4), 143.3
(C-19), 147.8 (C-6), 149.5 (C-5), 161.3 (C-12), 164.2 (C-15),
171.1 (C-13); LCMS (m/z): 448 (M+). Found: C-61.49, H-
4.46, N-12.52; Anal. Calcd. For C23H20N4O2S2 (448.10): C-
61.58, H-4.49, N-12.49%.
2.2.4.6. 2-{5-[4-(1-Aza-2-(2-thienyl)vinyl)phenyl](1,3,4-oxa-
diazol-2-ylthio)}-N-(3-methoxy-phenyl)acetamide (IV)6.
Yield: 85%; m.p.: light yellow crystal; 178–180 C; IR (KBr,
cm1): 3331 (–NH stretching, secondary amine), 3086, 3054
(C–H stretching, aromatic ring), 2935, 2869 (C–H stretching,
–OCH3 and –CH2), 1715 (C‚O stretching, amide), 1624,
1585, 1558 (C‚N, C‚C stretching, aromatic ring), 1454,
1415 (C–H bending, –CH2–, –OCH3), 1210 (C–O–C stretch-
ing, oxadiazole); 1H NMR (400 MHz, DMSO-d6, d, ppm):
3.62 (s, 3H, Ar–OCH3), 4.00 (s, 2H, –S–CH2–), 6.53–7.90
(m, 11H, ArH), 8.12 (s, 1H, N‚CH), 10.21 (s, 1H,
–CONH–); 13C NMR 400 MHz, DMSO-d6, d, ppm): 32.5
(C-14), 53.2 (C-22), 109.6 (C-17), 110.2 (C-21), 115.4 (C-19),
119.8 (C-7, 11), 124.6 (C-9), 127.2 (C-2), 128.5 (C-3), 128.9
(C-18), 129.0 (C-1), 131.3 (C-8, 10), 140.5 (C-16), 141.5 (C-
4), 147.8 (C-6), 149.8 (C-5), 158.8 (C-20), 161.2 (C-12), 164.5
(C-15), 171.3 (C-13); LCMS (m/z): 450 (M+). Found: C-
58.55, H-4.12, N-12.46; Anal. Calcd. For C22H18N4O3S2
(450.08): C-58.65, H-4.02, N-12.43%.
2.2.4.7. 2-{5-[4-(1-Aza-2-(2-thienyl)vinyl)phenyl](1,3,4-oxa-
diazol-2-ylthio)}-N-(3,4-dichloro- phenyl)acetamide (IV)7.
Yield: 60%; light brown crystal; m.p.: 211–213 C, IR (KBr,
cm1): 3336 (–NH stretching, secondary amine), 3088, 3056
(C–H stretching, aromatic ring), 2875 (C–H stretching,
–CH2–), 1718 (C‚O stretching, amide), 1629, 1588, 1556
(C‚N, C‚C, aromatic ring), 1445 (C–H bending, –CH2–),
1208 (C–O–C stretching, oxadiazole), 784 (C–Cl); 1H NMR
(400 MHz, DMSO-d6, d, ppm): 4.03 (s, 2H, –S–CH2–), 6.56–
7.88 (m, 10H, ArH), 8.15 (s, 1H, –CH‚N–), 10.23 (s, 1H,
–CONH). 13C NMR (400 MHz, DMSO-d6, d, ppm): 32.4
(C-14), 119.7 (C-7, 11), 121.2 (C-18), 124.3 (C-17), 124.5(C-
9), 127.2 (C-2), 128.4 (C-3), 129 (C-1), 130.5 (C-21), 131.2
(C-8, 10), 131.4 (C-20), 138 (C-16), 141.4 (C-4), 147.9 (C-6),
258 N.C. Desai et al.149.5 (C-5), 161.2 (C-12), 164.3(C-15), 171.4 (C-13); LCMS
(m/z): 487 (M+). Found: C-51.51, H-2.74, N-11.40; Anal.
Calcd. For C21H14Cl2N4O2S2 (487.99): C-51.53, H-2.88, N-
11.44%.
2.2.4.8. 2-{5-[4-(1-Aza-2-(2-thienyl)vinyl)phenyl](1,3,4-oxa-
diazol-2-ylthio)}-N-(4-ﬂuoro-phenyl)acetamide (IV)8. Yield:
76%; brown crystal; m.p.: 164–166 C; IR (KBr, cm1): 3337
(–NH stretching, secondary amine), 3085, 3057 (C–H stretch-
ing, aromatic ring), 2869 (C–H stretching, –CH2–), 1719
(C‚O stretching, amide), 1627, 1587, 1558 (C‚N, C‚C, aro-
matic ring stretching), 1450 (C–H bending, –CH2–), 1209 (C–
O–C stretching, oxadiazole), 1150 (C–F); 1H NMR
(400 MHz, DMSO-d6, d, ppm): 4.04 (s, 2H, –S–CH2–), 6.54–
7.90 (m, 11H, ArH), 8.15 (s, 1H, –CH‚N–), 10.24 (s, 1H,
–CONH); 13C NMR (400 MHz, DMSO-d6, d, ppm): 32.5
(C-14), 115.7 (C-18, 20), 119.7 (C-7, 11), 120.6 (C-17, 21),
124.7 (C-9), 127.1 (C-2), 128.6 (C-3), 129.1 (C-1), 131.3 (C-8,
10), 134.1 (C-16), 141.4 (C-4), 147.7 (C-6), 149.7 (C-5), 161.3
(C-12), 162.2 (C-19), 164.6 (C-15), 171.5 (C-13); LCMS (m/
z): 438 (M+). Found: C-57.65, H-3.52, N-12.59; Anal. Calcd.
For C21H15FN4O2S2 (438.06): C-57.52, H-3.44, N-12.77%.
2.2.4.9. 2-{5-[4-(1-Aza-2-(2-thienyl)vinyl)phenyl](1,3,4-oxa-
diazol-2-ylthio)}-N-(4-chloro-phenyl)acetamide (IV)9. Yield:
79%; light yellow crystal; m.p.: 196–198 C; IR (KBr, cm1):
3335 (–NH stretching, secondary amine), 3085, 3057 (C–H
stretching, aromatic ring), 2865 (C–H stretching, –CH2–),
1719 (C‚O stretching, amide), 1625, 1588, 1554 (C‚N,
C‚C, aromatic ring stretching), 1449 (C–H bending, –CH2–),
1206 (C–O–C stretching, oxadiazole), 780 (C–Cl); 1H NMR
(400 MHz, DMSO-d6, d, ppm): 4.02 (s, 2H, –S–CH2–), 6.52–
7.85 (m, 11H, ArH), 8.12 (s, 1H, –CH‚N–), 10.23 (s, 1H,
–CONH); 13C NMR (400 MHz, DMSO-d6, d, ppm): 32.4 (C-
14), 119.9 (C-7, 11), 120.1 (C-17, 21), 124.4 (C-9), 127.2 (C-2),
128.5 (C-3), 129.1 (C-1), 129.3 (18, 20), 131.3 (C-8, 10), 133.3
(C-19), 138.6 (C-16), 141.6 (C-4), 147.8 (C-6), 149.5 (C-5),
161.1 (C-12), 164.3 (C-15), 171.3 (C-13); LCMS (m/z): 454
(M+). Found: C-55.39, H-3.38, N-12.34; Anal. Calcd. For
C21H15ClN4O2S2 (454.05): C-55.44, H-3.32, N-12.31%.
2.2.4.10. 2-{5-[4-(1-Aza-2-(2-thienyl)vinyl)phenyl](1,3,4-oxa-
diazol-2-ylthio)}-N-(4-bromo-phenyl)acetamide (IV)10. Yield:
69%; light brown crystal; m.p.: 166–168 C; IR (KBr, cm1):
3337 (–NH stretching, secondary amine), 3084, 3057 (C–H
stretching, aromatic ring), 2868 (C–H stretching, –CH2–),
1715 (C‚O stretching, amide), 1627, 1590, 1557 (C‚N,
C‚C, aromatic ring stretching), 1451 (C–H bending, –CH2–),
1205 (C–O–C stretching, oxadiazole), 660 (C–Br); 1H NMR
(400 MHz, DMSO-d6, d, ppm): 4.04 (s, 2H, –S–CH2–), 6.52–
7.85 (m, 11H, ArH), 8.14 (s, 1H, –CH‚N–), 10.25 (s, 1H,
–CONH); 13C NMR (400 MHz, DMSO-d6, d, ppm): 32.5 (C-
14), 119.7 (C-7, 11) 121.9 (C-17, 21), 122.4 (C-19), 124.7 (C-9),
127.2 (C-2), 128.5 (C-3), 129.2 (C-1), 131.2 (C-8, 10), 131.7 (C-
18, 20), 137.5 (C-16), 141.4 (C-4), 147.5 (C-6), 149.8 (C-5),
161.2 (C-12), 164.6 (C-15), 171.1 (C-13); LCMS (m/z): 499
(M+). Found: C-50.66, H-3.16, N-11.27; Anal. Calcd. For
C21H15BrN4O2S2 (499.98): C-50.50, H-3.02, N-11.21%.
2.2.4.11. 2-{5-[4-(1-Aza-2-(2-thienyl)vinyl)phenyl](1,3,4-oxa-
diazol-2-ylthio)}-N-(4-nitro-phenyl)acetamide (IV)11. Yield:
76%; dark yellow crystal; m.p.: 152–154 C; IR (KBr, cm1):3339 (–NH stretching, secondary amine), 3088, 3055 (C–H
stretching, aromatic ring), 2867 (C–H stretching, –CH2–),
1716 (C‚O stretching, amide), 1628, 1587, 1554 (C‚N,
C‚C, aromatic ring stretching), 1468 (NO2 group, asymmetric
stretching), 1456 (C–H bending, –CH2–), 1356 (NO2 group,
symmetric stretching), 1210 (C–O–C stretching, oxadiazole);
1H NMR (400 MHz, DMSO-d6, d, ppm): 4.05 (s, 2H, –S–
CH2–), 6.62–7.9 (m, 11H, ArH), 8.16 (s, 1H, –CH‚N), 10.25
(s, 1H, –CONH–); 13C NMR (400 MHz, DMSO-d6, d, ppm):
32.6 (C-14), 119.7 (C-7, 11), 119.9 (C 17, 21) 124.2 (C-18, 20),
124.8 (C-9), 127.4 (C-2), 128.3 (C-3), 129.4 (C-1), 131.2 (C-8,
10), 141.6 (C-4), 143.5 (C-19), 145.6 (C-16), 147.6 (C-6), 149.6
(C-5), 161.4 (C-12), 164.5 (C-15), 171.5 (C-13); LCMS (m/z):
465 (M+). Found: C-54.15, H-3.17, N-15.07; Anal. Calcd. For
C21H15N5O4S2 (465.06): C-54.18, H-3.24, N-15.04%.
2.2.4.12. 2-{5-[4-(1-Aza-2-(2-thienyl)vinyl)phenyl](1,3,4-oxa-
diazol-2-ylthio)}-N-(4-methoxy-phenyl)acetamide (IV)12.
Yield: 81%; light yellow crystal; m.p.: 210–212 C; IR (KBr,
cm1): 3337 (–NH stretching, secondary amine), 3084, 3057
(C–H stretching, aromatic ring), 2868, 2943 (C–H stretching,
–CH2–, –OCH3), 1716 (C‚O stretching, amide), 1627, 1586,
1557 (C‚N, C‚C, aromatic ring stretching), 1454, 1418
(C–H bending, –CH2–, –OCH3), 1207 (C–O–C stretching, oxa-
diazole); 1H NMR (400 MHz, DMSO-d6, d, ppm): 3.64 (s, 3H,
–OCH3), 4.05 (s, 2H, –S–CH2–), 6.51–7.9 (m, 11H, ArH), 8.13
(s, 1H, –CH‚N), 10.23 (s, 1H, –CONH–); 13C NMR
(400 MHz, DMSO-d6, d, ppm): 32.5 (C-14), 53.8 (C-22),
114.5 (C-18, 20), 119.7 (C-7, 11), 122.8 (C-17, 21), 124.4 (C-
9), 127.3 (C-2), 128.4 (C-3), 129.1 (C-1), 130.8 (C-16), 131.2
(C-8, 10), 141.4 (C-4), 147.8 (C-6), 149.6 (C-5), 157.9 (C-19),
161.1 (C-12), 164.3 (C-15), 171.3 (C-13); LCMS (m/z): 450
(M+). Found: C-58.70, H-4.10, N-12.54; Anal. Calcd. For
C22H18N4O3S2 (450.8): C-58.65, H-4.02, N-12.43%.
3. Results and discussion
3.1. Synthesis
One of the most important feature in 2-aryl-5-substituted-
1,3,4-oxadiazoles chemistry is their use as a key starting mate-
rial for further transformations. The present scaffold (IV) is a
part of the synthesis of new chemical entities in the form of
antimicrobial agents. The title compounds (IV)1-12 were syn-
thesized in three steps. The ﬁrst step involves cyclization of
N-amino(4-aminophenyl)carboxamide (I) with carbon disul-
ﬁde and potassium hydroxide in ethanol (95%) to give 5-(4-
aminophenyl)-1,3,4-oxadiazole-2-thiol (II). Compound (II)
on condensation with thiophene-2-carbaldehyde yielded 5-[4-
(1-aza-2-(2-thienyl)vinyl)phenyl]-1,3,4-oxadiazole-2-thiol (III).
Finally, compound (III) on treatment with different substi-
tuted a-chloro acetanilides in alkaline media furnished 2-{5-
[4-(1-aza-2-(2-thienyl)vinyl)phenyl](1,3,4-oxadiazol-2-ylthio)}-
N-arylacetamides (IV)1–12. The scheme of synthetic procedure
for preparation of title compounds is given in (Scheme 1).
3.2. Characterization
The IR spectrum of the title compound (IV)6 (molecular for-
mula C22H18N4O3S2, m.w. 450.08) has given stretching vibra-
tion at 3331 cm1 over the range, which showed medium
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Scheme 1 Synthetic route of the ﬁnal compounds (IV)1–12.
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which is present in amide linkage. The vibration at 3086 and
3054 cm1 over the range showed strong intensity absorption
peaks corresponding to Thi–H and Ar–H stretching vibra-
tions. The absorption peaks at 2935 and 2869 cm1 are due
to the stretching vibration corresponding to the methoxy and
methylene groups, while the absorption peaks at 1415 and
1454 cm1 are due to the bending vibration corresponding to
methoxy and methylene group. The strong intensity absorp-
tion at 1715 cm1 is due to the stretching vibration of C‚O
which is present in amide linkage. The weak intensity absorp-
tion at 1624 cm1 corresponds to a C‚N stretching vibration,
while C‚C showed medium intensity absorption stretching
vibration at 1558 and 1588 cm1. The absorption peaks in
the range of 1210 cm1 correspond to C–O–C linkage of oxa-
diazole nucleus.
It has been observed from the chemical structure of com-
pound (IV)6 that different pairs of carbons, e.g., C-11 and C-
7, C-8 and C-10 are attached to chemically equivalent protons,
which appeared at d= 7.56 and 7.9 ppm, respectively. The
protons attached at C-14 appeared as a singlet at
d= 4.00 ppm due to one side attachment with sulfur and
other side attachment with carbonyl group. The protons of
methoxy group appeared as a singlet at d= 3.6 ppm, while
protons attached with carbons C-1, C-2 and C-3 in thiophine
appeared between d= 6.95–7.30 ppm respectively. The protonattached at C-5 position appeared as a singlet at
d= 8.12 ppm, due to the inﬂuence of the imine linkage. The
proton of the secondary amine appeared as a singlet at
d= 10.2 ppm. The protons attached with C-17, C-18, C-19
and C-21 of methoxy phenyl ring appeared as a multiplet at
d= 6.53-7.56 ppm respectively.
The ﬁnal compound (IV)6 has oxadiazole and thiophine
rings. The chemical shifts of the ﬁnal compound carbon vary
from d= 171.2–32.5 ppm. The carbon nucleus under the inﬂu-
ence of a strong electronegative environment appeared down-
ﬁeld, e.g. the C-15 carbonyl carbon, which is present in amide
linkage, which is directly linked to nitrogen, has a chemical
shift value of d= 164.5 ppm. The carbons which are present
in oxadiazole nucleus C-12 and C-13 both are on one side
and directly attached with oxygen atom and on other side at-
tached with nitrogen. So, carbon C-12 gave a chemical shift at
d= 161.2 ppm and C-13 gave a chemical shift at
d= 171.2 ppm. Carbon C-13 was more downﬁeld than C-12
because it is directly attached with sulfur. Carbon C-20 ap-
peared at d= 158.8 ppm due to the inﬂuence of methoxy
group. The carbon which is present in imine linkage C-5 gave
a chemical shift at d= 149.8 ppm. The carbon C-6 appeared
at d= 147.8 ppm because it is attached with nitrogen of imine.
The carbons which are present in thiophene ring C-1, C-2, C-3
and C-4 gave a chemical shift between d= 127.2–141.4 ppm
respectively. The carbon C-14 appeared at d= 32.5 ppm due
to the inﬂuence of electronegativity of carbonyl group and sul-
fur. The carbon C-9 of the phenyl ring which is directly at-
tached to oxadiazole ring appeared at d= 124.6 ppm. The
carbons of the phenyl ring C-7 and C-11 which are equivalent
carbons gave a chemical shift at d= 119.8 ppm, while carbons
C-8 and C-10 which are also equivalent gave a chemical shift at
d= 131.3 ppm. The carbon C-16 appeared at d= 140.5 ppm
due to the inﬂuence of amide linkage. The carbons of methoxy
phenyl ring C-17, C-18, C-19 and C-21 gave a chemical shift
between d= 109.6-128.9 ppm respectively. Carbon enumera-
tion of compound (IV)6 is described in (Fig. 1).
3.3. Antimicrobial screening
The results of antimicrobial studies of newly synthesized com-
pounds reveal that the compounds possess signiﬁcant antibac-
terial and antifungal activities. The results of these studies are
given in (Table 1). From antibacterial screening results, it has
been observed that compounds (IV)8 and (IV)9 (R = –4-F and
–4-Cl) possess good activity against E. coli. While compounds
(IV)6 and (IV)10 (R = –3-OCH3 and –4-Br) possess very good
activity against E. coli and compounds (IV)5 and (IV)7
(R = 2,4(CH3)2 and 3,4-(Cl)2) possess excellent activity
against E. coli. Compounds (IV)2, (IV)6 and (IV)10 (R =
–2-Cl, –3-OCH3 and –4-Br) possess good activity against P.
aeruginosa. While compound (IV)9 (R = –4-Cl) possesses a
very good activity against P. aeruginosa and compound (IV)5
(R = –2,4(CH3)2) possesses excellent activity against P. aeru-
ginosa. Compounds (IV)3, (IV)4, (IV)7 and (IV)12 (R = –2-
NO2, –2-CH3, –3,4-(Cl)2, and –4-OCH3) possess good activity
against S. aureus. While compounds (IV)1, (IV)5, (IV)8, (IV)9,
(IV)10 and (IV)11 (R = –H, –2,4(CH3)2, –4-F, –4-Cl, –4-Br,
4-NO2) possess very good activity against S. aureus and com-
pound (IV)6 (R = –3-OCH3) possesses excellent activity
against S. aureus. Compounds (IV)6 and (IV)10 (R =
NO S
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Figure 1 Carbon enumeration of the ﬁnal compound-(IV)6.
Table 1 Results of antibacterial and antifungal screening of compounds (IV)1–12.
S. no. –R Minimum inhibitory concentration (MIC) lg/mL ± SD Minimum inhibitory concentration (MIC) in lg/mL± SD
E. coli P. aeruginosa S. aureus S. pyogenes C. albicans A. niger A. clavatus
MTCC 443 MTCC 1688 MTCC 96 MTCC 442 MTCC 227 MTCC 282 MTCC 1323
(IV)1 H 500 ± 4.93
* 250 ± 2.64* 100 ± 3.78* 1000 ± 2.64* 500 ± 3.78* 500 ± 3.05* 500 ± 3.21*
(IV)2 2-C1 250 ± 3.05
* 100 ± 3.46* 500 ± 3.21* 500 ± 4.04* 500 ± 3.05* 500 ± 3.51* 500 ± 4.05*
(IV)3 2-NO2 250 ± 3.78
* 250 ± 3.21* 250 ± 2.08* 250 ± 2.51* 250 ± 3* 500 ± 4.50* 500 ± 4.35*
(IV)4 2-CH3 500 ± 4.50
* 250 ± 3.51* 250 ± 2.08* 250 ± 2.64* 500 ± 4.50* 100 ± 4.21* 500 ± 4.16*
(IV)5 2,4-(CH3)2 25 ± 1
* 25 ± 1* 100 ± 4.04* 500 ± 2.51* 1000 ± 3.21* 250 ± 2.08* 250 ± 3.78*
(IV)6 3-OCH3 50 ± 4
* 100 ± 3.60* 50 ± 3.78* 100 ± 3.78* 125 ± 4.04* 1000 ± 3.05* 500 ± 3.78*
(IV)7 3,4-(Cl)2 25 ± 1
* 500 ± 4.72* 250 ± 3.05* 250 ± 3.51* 1000 ± 3.05* 500 ± 4.05* 500 ± 3.51*
(IV)8 4-F 100 ± 4.72
* 250 ± 3.05* 100 ± 4.16* 500 ± 3.78* 1000 ± 4.04* 1000 ± 4* 1000 ± 3.05*
(IV)9 4-C1 100 ± 4.58
* 50 ± 4* 125 ± 4.04* 500 ± 4.50* 100 ± 4.93* 250 ± 3.78* 500 ± 4.58*
(IV)10 4-Br 50 ± 4.05
* 100 ± 4.16* 100 ± 4.50* 100 ± 3.05* 1000 ± 3.21* 1000 ± 3.05* 1000 ± 3.21*
(IV)11 4-NO2 250 ± 3.21
* 500 ± 3* 125 ± 2.64* 250 ± 2.08* 100 ± 2.30* 250 ± 3.05* 500 ± 3.46*
(IV)12 4-OCH3 250 ± 3.05
* 250 ± 3.78* 250 ± 3.21* 500 ± 3.51* 500 ± 2.51* 1000 ± 2.64* 1000 ± 4*
Ampicillin 100 ± 2.05* 100 ± 1.0* 250 ± 1.52* 100 ± 2.06* – – –
Griseofulvin – – – – 500 ± 0.58* 100 ± l* 100 ± 1.15*
SD= standard deviation.
* p< 0.0001.
260 N.C. Desai et al.–3-OCH3, –4-Br) possess good activity against S. pyogenes.
Antifungal screening data showed that compounds (IV)1,
(IV)2, (IV)4 and (IV)12 (R = –H, –2-Cl, –2-CH3 and –4-
OCH3) possess good activity against C. albicans. While com-
pound (IV)3 (R = –2-NO2) possesses good activity against
C. albicans and Compounds (IV)6, (IV)9 and (IV)11 (R = 3-
OCH3, 4-Cl and 4-NO2) possess excellent activity against C.
albicans. Compound (IV)4 (R = –2-CH3) possesses good activ-
ity against A. niger. The enhancement of the activity of these
compounds is due to the presence of methyl, methoxy and hal-
ogen groups in the title compounds. The discussion and com-
parison of antibacterial activity was given with respect to
ampicillin antibiotic. In a similar manner, antifungal activity
was compared with griseofulvin.
3.4. Antibacterial activity assay
The newly synthesized compounds were screened for their anti-
bacterial activity against gram positive bacteria Staphylococcus
aureus (MTCC 96) , Staphylococcus pyogenes (MTCC 442) and
gram negative bacteria Escherichia coli (MTCC 443), Pseudo-
monas aeruginosa (MTCC 1688). Antibacterial activity was
carried out by serial broth dilution method (Ghalem and
Mohamed, 2009); (Desai and Trivedi, 1993); (Al-Bayati and
Al-Mola, 2008); (Desai et al., 2010). The standard strains used
for the antimicrobial activity was procured from The Institute
of Microbial Technology, Chandigarh. The compounds (IV)1–
12 were screened for their antibacterial activity in triplicate
against Escherichia coli, Staphylococcus aureus, Pseudomonasaeruginosa and Staphylococcus pyogenes at different concentra-
tions of 1000, 500, 200, 100, 50, 25, 12.5 lg/mL as shown in
(Table 1). The drugs found to be active in primary screening
were similarly diluted to obtain 100, 50, 25, 12.5 lg/mL con-
centrations. 10 lg/mL suspensions were further inoculated on
appropriate media and growth was noted after 24 and 48 h.
The lowest concentration, which showed no growth after spot
subculture was considered as MIC for each drug. The highest
dilution showing at least 99% inhibition is taken as (MIC).
The test mixture should contain 108cell/mL. The standard drug
used in the present study was ‘‘ampicillin’’ for evaluating anti-
bacterial activity which showed (100, 100, 250 and 100 lg/mL)
MIC against E. coli, P. aeruginosa, S. aureus and S. pyogenes
respectively.
3.5. Antifungal activity assay
The same compounds were tested for antifungal activity in
triplicate against Candida albicans, Aspergillus niger and
Aspergillus clavatus at various concentrations of 1000, 500,
200, 100 lg/mL as shown in (Table 1). The results were re-
corded in the form of primary and secondary screening. The
synthesized compounds were diluted at 1000 lg/mL concentra-
tion, as a stock solution. The synthesized compounds which
were found to be active in this primary screening were further
tested in a second set of dilution against all microorganisms.
The lowest concentration, which showed no growth after spot
subculture was considered as MIC for each drug. The highest
dilution showing at least 99% inhibition is taken as MIC. The
Synthesis and antimicrobial screening of 1,3,4-oxadiazole and clubbed thiophene derivatives 261test mixture should contain 108 spores/mL MIC. ‘‘Griseoful-
vin’’ was used as a standard drug for antifungal activity, which
showed (500, 100 and 100 lg /mL) MIC against C. albicans, A.
niger and A. clavatus, respectively.
3.6. Statistical analysis
The standard deviation value is expressed in terms of ±SD.
On the basis of the calculated value by using ANOVA method,
it has been observed that differences below 0.0001 level
(p 6 0.0001) were considered as statistically signiﬁcant.
4. Conclusion
The outstanding properties of this new class of antimicrobial
substances deserve further investigation in order to clarify
the mode of action at molecular level responsible for the activ-
ity observed. An extensive study is also warranted to determine
additional physiochemical and biological parameters to have a
deeper insight into its structure–activity relationship and to
optimize the effectiveness of this series of molecules.Acknowledgement
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